Key result
Poncirus trifoliata aqueous extract protected against doxorubicin-induced cardiotoxicity in mice and cardiomyocytes by restoring cell viability and electrophysiological parameters.
Why the study?
Prolonged doxorubicin treatment causes cardiotoxicity, and no effective method is currently available to overcome it.
Does Poncirus trifoliata aqueous extract protect against doxorubicin-induced cardiotoxicity in preclinical models?
Population
H9c2 rat cardiomyocytes, MDA-MB-231 cells, and C57BL/6 mice
Comparison
Poncirus trifoliata aqueous extract vs controls in doxorubicin-induced cardiotoxicity
Design
Preclinical in vitro and in vivo animal study
Authors
Loading...
Should not yet change practice for DICT; leaves open whether PTA or NQO1 induction warrants human trials.
Does Poncirus trifoliata aqueous extract protect against doxorubicin-induced cardiotoxicity in preclinical models?
Poncirus trifoliata aqueous extract demonstrates protective effects against doxorubicin-induced cardiotoxicity in preclinical models through antioxidant mechanisms involving NQO1 upregulation.
Kim et al. (2023) studied Doxorubicin-induced cardiotoxicity. Poncirus trifoliata aqueous extract (PTA) vs. Doxorubicin alone was evaluated on Cell viability, electrophysiological characteristics, serum biomarkers, and histological features. Poncirus trifoliata aqueous extract protected against doxorubicin-induced cardiotoxicity in mice and cardiomyocytes by restoring cell viability and electrophysiological parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: